H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Zevra Therapeutics to $15 from $10 and keeps a Buy rating on the shares. The company is heading into a “transformational” 2024, the analyst tells investors in a research note. The new price target reflects “just” 50% probability of arimoclomol success and the company can generate meaningful value even without it, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZVRA:
- Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
- Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
- Zevra Therapeutics completes acquisition of Acer Therapeutics
- Zevra Therapeutics price target raised to $24 from $20 at Canaccord
- Zevra Therapeutics price target lowered to $22 from $25 at Roth MKM
